AstraZeneca 2023 ESMO - Meet AZN Management (2023-10-23)

 

ESMO-IR-deck-Oct-2023.pdf

9.91MB

ESMO-IR-posters-Oct-2023.pdf

2.94MB

 

https://www.astrazeneca.com/content/astraz/investor-relations/meet-azn-management-esmo-congress-2023.html

Meet AZN management: European Society for Medical Oncology (ESMO) Congress 2023

2023 ESMO에서 AstraZeneca가 Investor Event한 자료 (2023-10-23)

 

ADC @ AstraZeneca:

 

 

Bispecfiics @ AstraZeneca:

결과들이 재밌게 나오는 이중항체들

Volrustomig (PD-1 x CTLA-4)

Rilvegostomig (PD-1 x TIGIT)

Sabestomig (PD-1 x TIM3)

 

PD-1은 어떤 mAb epitope과 binding이 같으려나?

Rilvegostomig의 TIGIT은 Compugen으로부터 기술이전 해온 antibody 부분

 

Volrustomig (PD-1 x CTLA-4) in 1L advanced ccRCC

 

Rilvegostomig (PD-1 x TIGIT) in CPI-experienced NSCLC [ARTEMIDE-01]

 

Sabestomig (PD-1 x TIM3) in Stage IIIb-IV NSCLC with prior PD-1 therapy

 

 

AstraZeneca의 NSCLC 전략: